Thus, JNK activation had been shown to promote tumor proliferation, as demonstrated in glioblastoma (28), non-small cell lung cancer (NSCLC) (29) and pancreatic cancer (30, 31), or to immune evasion as in breast (32) and oropharynx cancers (33). Here, MAPK8 is linked to non-small cell lung carcinoma.